

SFG SCIENCES Inc. and

SFG Drug Discovery Fund #1

June, 2023

The Founder



Hiroshi Nagabukuro, Ph.D.



SFG SCIENCES Inc.
Managing Partner



ARTham Therapeutics Inc.
President CEO
(Resigning in June 2023)



Clinical Pharmacology, Faculty of Med
Oita University
Translational & Clinical Science
Adjunct Professor



Clinical Research, Innovation and Education
Center, Tohoku University Hospital
Visiting Professor



**Korea Health Industry Development Institute
Global Pharma Key Opinion Leader**

Korea Health Industry Development Institute

Certificate of Global Pharma Key Opinion Leader(GPKOL)

This is to certify that

Hiroshi Nagabukuro

*is a member of Korea Health Industry Development Institute's Global Pharma
Key Opinion Leader(GPKOL) with all the rights, privileges and honors.*

This certificate is hereby issued in December, 2022

A handwritten signature in black ink, likely belonging to Soon-do Cha, President of KHIDI.

Soon-do Cha Ph.D., President of KHIDI

SFG SCIENCES inc.

“Investment firm/pharma R&D platform to nurture global entrepreneurship mind”

“A group of drug discovery professionals led by ARTham founding members and life science business professionals”

- Identify assets and target indications from pharma assets on the shelf
- Incorporate special purposed entities (SPE) based on the identified assets
- Collaboration with originator pharmacos to drive global R&D
- M&A exit of SPE to global pharmaco
- Nurture Entrepreneurs in Japan and South Korea

SFG SCIENCES Leadership



Hiroshi Nagabukuro, PhD
Managing Partner
 CEO ARTham Therapeutics
 Adjunct Professor Oita University




Kyohei Tanaka, CPA
Partner
 Founder of investment hub Inc.



Akira Tanaka, PhD
Executive Officer
 ARTham Therapeutics
 Vice President




SFG SCIENCES team members



Kanako Kuniyeda, PhD
Executive Director
ARTham Therapeutics
Director



Dnyaneshwar Warude, PhD
Executive Director
Takeda Associate Director




OO OO, PhD
Executive Director
Venture Capital Firm



Yuka Stromsodd
Manager
ARTham Therapeutics
Accounting/HR manager



Nobuyo Ozawa
Director
Accerise Manager



**Entrepreneurs
in Residence**
(from pharma)



- Translational research
- Preclinical development
- Clinical research



- Translational research
- Preclinical development

Japanese VC



- Asset sourcing
- IR
- Medicinal chemistry
- Target validation



- Accounting
- HR



- Clinical operation
- Project management



etc.

SFG SCIENCES advisory board



**Naoto Uemura,
MD, PhD**

Professor
Clin Pharmacology,
Oita University




**Misako Hamamura,
PhD**

Head
Rare Disease Business Unit



Matt Devalaraja, PhD

Nipuna Therapeutics CEO



Ken Ishii MD, PhD

Professor Division of
Vaccine Science
The Institute of Medical
Science
The University of Tokyo.




Steve Engen

CEO
Renexes



Sham Nikam, PhD

Co-founder
ARTham Therapeutics




Felix Woo, CPA



東京大学
The University of Tokyo



What SFG is aiming for: a true drug discovery ecosystem



Contact

Hiroshi Nagabukuro
SFG SCIENCES Inc.
hiroshi.nagabukuro@sfgosci.com
+81-80-2436-7935